Clinical Development

Research & Development

Verséa is evaluating new drug candidates (new chemical and botanical entities) and delivery approaches of ethical pharmaceuticals to address medical needs. Our medical hemp research is focused on studying components of the hemp plant individually and in combinations to assess in vitro and in vivo response across multiple body systems. Physiologic response determines the therapeutic target for each candidate. This process allows Verséa to build a pipeline of New Chemical Entities (NCEs) and Botanical Rx drug candidates. Areas of interest to Verséa for ethical drug, botanical drug, and product development are:

  • Pain
  • Inflammation
  • Anxiety and Mood Disorders
  • Disorders of the Central Nervous System
  • Cancer
  • Infectious Disease

Breeding Program

The Verséa breeding program is designed to translate lab-created New Chemical Entities (NCEs) to botanical chemovars that are replicated and scaled for cultivation. Innovative techniques and processes will allow for the rapid scale up to produce botanical drug substances and novel drug products for clinical trials through the Rx Botanical program. During this discovery and development effort, Verséa may discover an NCE that warrants pharmaceutical development as a single agent (versus component of a botanical drug substance).

Clinical Timeline

Our clinical program is aimed at advancing NCE and Rx Botanical candidates towards global market approvals. The initial focus of Verséa is on the Rx Botanical clinical program. The near-term goal of this program is to submit Investigational New Drugs (INDs) for various hemp-derived Rx Botanical candidates. Verséa is positioned to a first mover in this market segment.

Portfolio of development candidates will have the necessary quality studies performed positioning them for advanced clinical development.